I already did, and the opinion I got is that unless this drug can show the levels of proteinuria reductions (>50%) and complete/partial remission rates seen with standard of care immunosuppression like steroids, the dimx drug may have limited use. We already know this is a class of drug ccr2 I, that doesn’t have good track record and been shown to be a bit mediocre in kidney diseases with proteinuria.
Ann: Investor Presentation, page-109
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
57.5¢ |
Change
0.005(0.88%) |
Mkt cap ! $302.3M | |||
| Open | High | Low | Value | Volume |
| 56.0¢ | 58.5¢ | 54.0¢ | $2.354M | 4.216M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 7253 | 57.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 58.0¢ | 111711 | 4 |
View Market Depth
| Last trade - 13.34pm 19/06/2024 (20 minute delay) ? |
| DXB (ASX) Chart |